Amyloid Solution Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
2ndary - Private
- Investors
-
17
Amyloid Solution General Information
Description
Developer of therapy drugs intended for the treatment of Alzheimer's at different stages. The company offers drug discovery programs, an amyloid research platform, and a therapeutic development pipeline to find disease-modifying novel therapeutics, enabling researchers and healthcare organizations to develop and evaluate potential treatments for Alzheimer's disease.
Contact Information
Website
www.amyloidsolution.comCorporate Office
- Number 601, C's Tower, 58
- Pangyo-ro 255beon-gil, Bundang-gu
- Seongnam, Gyeonggi 13486
- South Korea
Corporate Office
- Number 601, C's Tower, 58
- Pangyo-ro 255beon-gil, Bundang-gu
- Seongnam, Gyeonggi 13486
- South Korea
Amyloid Solution Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 6. Later Stage VC (Series C) | 04-May-2022 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC (Series B) | 07-May-2020 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 26-Mar-2019 | Completed | Pre-Clinical Trials | |||
| 3. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 2. Accelerator/Incubator | 01-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 30-Nov-2017 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Amyloid Solution Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amyloid Solution Patents
Amyloid Solution Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4755889-A1 | Compound for detecting amyloid-beta oligomer and method for diagnosing degenerative brain disease using same | Pending | 31-May-2024 | ||
| WO-2025249975-A1 | Compound for detecting amyloid-beta oligomer and method for diagnosing degenerative brain disease using same | Pending | 31-May-2024 | ||
| EP-4745117-A1 | Novel indenone derivative and use thereof | Pending | 28-Dec-2023 | ||
| WO-2025143888-A1 | Novel indenone derivative and use thereof | Inactive | 28-Dec-2023 | ||
| WO-2024076210-A1 | Method for screening for candidate material for inhibiting or disaggregating amyloid protein aggregation | Inactive | 07-Oct-2022 |
Amyloid Solution Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amyloid Solution Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Heungkuk Securities | Corporation | Minority | ||
| Industrial Bank of Korea | PE/Buyout | Minority | ||
| Korea Investment & Securities | Asset Manager | Minority | ||
| SK Securities | Corporation | Minority | ||
| Woori Venture Partners | Venture Capital | Minority |
Amyloid Solution Investments & Acquisitions (3)
Amyloid Solution’s most recent deal was a Merger/Acquisition with Deargen. The deal was made on 02-Nov-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Deargen | 02-Nov-2020 | Merger/Acquisition | Drug Discovery | ||
| Deargen | 26-Oct-2020 | Seed Round | Drug Discovery | ||
| Neuramedy | 28-Oct-2019 | Seed Round | Drug Discovery |
Amyloid Solution Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Deargen | Daejeon, South Korea | 2016 |
Amyloid Solution FAQs
-
When was Amyloid Solution founded?
Amyloid Solution was founded in 2017.
-
Where is Amyloid Solution headquartered?
Amyloid Solution is headquartered in Seongnam, South Korea.
-
What is the size of Amyloid Solution?
Amyloid Solution has 27 total employees.
-
What industry is Amyloid Solution in?
Amyloid Solution’s primary industry is Drug Discovery.
-
Is Amyloid Solution a private or public company?
Amyloid Solution is a Private company.
-
What is Amyloid Solution’s current revenue?
The current revenue for Amyloid Solution is .
-
How much funding has Amyloid Solution raised over time?
Amyloid Solution has raised $65.4M.
-
Who are Amyloid Solution’s investors?
Heungkuk Securities, Industrial Bank of Korea, Korea Investment & Securities, SK Securities, and Woori Venture Partners are 5 of 17 investors who have invested in Amyloid Solution.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
